Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes

Cancer Research

Volumn 58, Issue 18, 1998, Pages 4023-4037

  Hussain, S Perwez ^a   Harris, Curtis C ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; GENE MUTATION; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; CARCINOGENS; CAUSALITY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE SUSCEPTIBILITY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY, MOLECULAR; GENES, BRCA1; GENES, P53; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PHENOTYPE; TRANSCRIPTION FACTORS;

EID: 0032530215     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (233)

1. Doll, R. Nature and nurture: possibilities for cancer control. Carcinogenesis (Lond.). 17: 177-184, 1996.
2. Couch, D. B. Carcinogenesis: basic principles. Drug Chem. Toxicol., 19: 133-148, 1996.
3. Yuspa, S. H., and Shields, P. G. Etiology of cancer: chemical. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 185-202. Philadelphia: Lippincott-Raven Publishers, 1997.
4. Weston, A., and Harris, C. C. Chemical Carcinogenesis. In: J. F. Holland, R. C. Bast, Jr., D. L. Morton, E. Frei III, D. W. Kufe, and R. R. Weichselbaum (eds.), Cancer Medicine, pp. 261-276. Baltimore, MD: Williams & Wilkins, 1997.
5. National Research Council. Assessment of toxicology. In: National Academy of Sciences (ed.), Science and Judgement in Risk Assessment, pp. 56-67. Washington, DC: National Academy Press, 1994.
6. Shields, P. G., and Harris, C. C. Molecular epidemiology and the genetics of environmental cancer. J. Am. Med. Assoc., 266: 681-687, 1991.
7. Perera, F. P., and Santella, R. Carcinogenesis. In: P. Schulte and F. P. Perera (eds.), Molecular Epidemiology: Principles and Practices, pp. 277-300. New York: Academic Press, 1993.
8. Harris, C. C. The Walter Hubert Lecture. Molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumor suppressor gene. Br. J. Cancer, 73: 261-269, 1996.
9. Perera, F. P. Environment and cancer: who are susceptible? Science (Washington DC), 278: 1068-1073, 1997.
10. Hunter, D., and Caporaso, N. Informed consent in epidemiologic studies involving genetic markers. Epidemiology, 8: 596-599, 1997.
11. Schulte, P. A., Hunter, D., and Rothman, N. Ethical and social issues in the use of biomarkers in epidemiological research. IARC Scientific Publ., 142, 313-318, 1997.
12. Harris, C. C. Chemical and physical Carcinogenesis: advances and perspectives for the 1990s. Cancer Res., 51 (Suppl.): 5023s-5044s, 1991.
13. Perera, F. P. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J. Natl. Cancer Inst., 88: 496-509, 1996.
14. Kinzler, K. W., and Vogelstein, B. Gatekeepers and caretakers. Nature (Lond.), 386: 761-763, 1997.
15. Ponder, B. Genetic testing for cancer risk. Science (Washington DC), 278: 1050-1054, 1997.
16. Li, F. P., Garber, J. E., Friend, S. H., Strong, L. C., Patenaude, A. F., Juengst, E. T., Reilly, P. R., Correa, P., and Fraumeni, J. F., Jr. Recommendations on predictive testing for germline p53 mutations among cancer-prone individuals. J. Natl. Cancer Inst..84: 1156-1160, 1992.
17. Soskolne, C. L. Ethical, social, and legal issues surrounding studies of susceptible populations and individuals. Environ. Health Perspect., 105 (Suppl. 4): 837-841, 1997.
18. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
19. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
20. Ponder, B. Cancer. Gene losses in human tumours. Nature (Lond.), 335: 400-402, 1988.
21. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
22. Fearon, E. R. Human cancer syndromes: clues to the origin and nature of cancer. Science (Washington DC), 278: 1043-1050, 1997.
23. Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science (Washington DC), 275: 1787-1790, 1997.
24. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell, 87: 159-170, 1996.
25. Levy, D. B., Smith, K. J., Beazer-Barclay, Y., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res., 54: 5953-5958, 1994.
26. Jen, J., Powell, S. M., Papadopoulos, N., Smith, K. J., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Molecular determinants of dysplasia in colorectal lesions. Cancer Res., 54: 5523-5526, 1994.
27. + in intestinal adenomas from Min mice. Cancer Res., 54: 5947-5952, 1994.
28. Prolla, T. A., Abuin, A., and Bradley. A. DNA mismatch repair deficient mice in cancer research. Semin. Cancer Biol., 7: 241-247, 1996.
29. de Wind, N., Dekker, M., Berns, A., Radman, M., and te Riele, H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell, 82: 321-330, 1995.
30. Reitmair, A. H., Schmits, R., Ewel, A., Bapat. B., Redston, M., Mitri, A., Water-house, P., Mittrucker, H. W., Wakeham, A., and Liu, B. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat. Genet., 11: 64-70, 1995.
31. Loeb, L. A. Mutator phenotype may be required for multistage Carcinogenesis. Cancer Res., 51: 3075-3080, 1991.
32. Loeb, L. A. Cancer cells exhibit a mutator phenotype. Adv. Cancer Res., 72: 25-56. 1998.
33. Aaltonen, L. A., Peltomaki, P., Leach, F. S., Sistonen, P., Pylkkanen, L., Mecklin, J. P., Jarvinen, H., Powell, S. M., Jen, J., Hamilton. S. R., Peterson, G. M., Kinzler, K. W., Vogelstein, B., and de la Chapelle, A. Clues to the pathogenesis of familial colorectal cancer. Science (Washington DC), 260: 812-815, 1993.
34. Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., and Perucho, M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonie Carcinogenesis. Nature (Lond.), 363: 558-561, 1993.
35. Thibodeau, S. N., Bren, G., and Schaid, D. Microsatellite instability in cancer of the proximal colon. Science (Washington DC), 260: 816-819, 1993.
36. Fishel, R., Lescoe, M. K., Rao, M. R., Copeland, N. G., Jenkins, N. A., Garber, J., Kane, M., and Kolodner, R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell, 75: 1027-1038, 1993.
37. Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomaki, P., Sistonen, P., Aaltonen, L. A., Nystrom-Lahti, M., Guan, X. Y., Zhang, J., Meltzer, P. S., Yu, J. W., Kao, F. T., Chen, D. J., Cerosaletti, K. M., Fournier, R. E., Todd, S., Lewis, T., Leach, R. J., Naylor, S. L., Weissenbach, J., Mecklin, J. P., Jarvinen, H., Petersen, G. M., Hamilton, S. R., Green, J., Jass, J., Watson, P., Lynch, H. T., Trent, J. M., de la Chapelle, A., Kinzler, K. W., and Vogelstein, B. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 75; 1215-1235, 1993.
38. Papadopoulos, N., Nicolaides, N. C., Wei, Y. F., Ruben, S. M., Carter, K. C., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., Adams, M. D., Venter, J. C, Hamilton, S. R., Petersen, G. M., Watson, P., Lynch, H. T., Peltomaki, P., Mecklin, J. P., de la Chapelle, A., Kinzler, K. W., and Vogelstein, B. Mutation of a mutL homolog in hereditary colon cancer. Science (Washington DC), 263: 1625-1629, 1994.
39. Nicolaides, N. C., Papadopoulos, N., Liu, B., Wei, Y. F., Carter. K. C., Ruben, S. M., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., and Fraser, C. M. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (Lond.), 371: 75-80, 1994.
40. Andrew, S. E., McKinnon, M., Cheng, B. S., Francis, A., Penney, J., Reitmair, A. H., Mak, T. W., and Jirik, F. R. Tissues of MSH2-deficient mice demonstrate hyper-mutability on exposure to a DNA methylating agent. Proc. Natl. Acad. Sci. USA, 95: 1126-1130, 1998.
41. Miyaki, M., Konishi, M., Tanaka, K., Kikuchi-Yanoshita, R., Muraoka, M., Yasuno, M., Igari, T., Koike, M., Chiba, M., and Mori, T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat. Genet., 17: 271-272, 1997.
42. Edelmann, W., Yang, K., Umar, A., Heyer, J., Lau, K., Fan, K., Liedtke, W., Cohen, P. E., Kane, M. F., Lipford, J. R., Yu, N., Crouse, G. F., Pollard, J. W., Kunkel, T., Kipkin, M., Kolodner, R., and Kucherlapati, R. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell, 91: 467-477, 1997.
43. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
44. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
45. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J. M., Wang, Z., Freidberg, E. C, Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H., Forrester, K., and Harris, C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10: 188-195, 1995.
46. Ford, J. M., and Hanawalt, P. C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV-resistance. Proc. Natl. Acad. Sci. USA, 92: 8876-8880, 1995.
47. Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr. Involvement of the p53 tumor suppressor in repair of UV-type DNA damage. Oncogene. 10: 1053-1059, 1995.
48. Mirzayans, R., Enns, L., Dietrich, K., Barley, R. D., and Paterson, M. C. Faulty DNA polymerase δ/δ-mediated excision repair in response to γ radiation or ultra-violet light in p53-deficient fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome. Carcinogenesis (Lond.), 17: 691-698, 1996.
49. Ford, J. M., and Hanawalt, P. C. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem., 272: 28073-28080, 1997.
50. Ford, J. M., Baron, E. L., and Hanawalt, P. C. Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Res., 58: 599-603, 1998.
51. Prost, S., Bellamy, C. O., Cunningham, D. S., and Harrison, D. J. Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes. FASEB J., 12: 181-188, 1998.
52. Mekeel, K. L., Tang, W., Kachnic, L. A., Luo, C. M., DeFrank, J. S., and Powell, S. N. Inactivation of p53 results in high rates of homologous recombination. Oncogene. 14: 1847-1857, 1997.
53. Meyn, M. S., Strasfeld, L., and Alien, C. Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia-telangiectasia. Int. J. Radiat. Biol., 66 (Suppl.): S141-S149, 1994.
54. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G. F. Abnormal centrosome amplification in the absence of p53. Science (Washington DC), 271: 1744-1747, 1996.
55. Kawashima, K., Mihara, K., Usuki, H., Shimizu, N., and Namba, M. Transfected mutant p53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1 -oxide but does not induce neoplastic transformation of the cells. Int. J. Cancer, 61: 76-79, 1995.
56. Xia, F., Wang, X., Wang, Y. H., Tsang, N. M., Yandell, D. W., Kelsey, K. T., and Liber, H. L. Altered p53 status correlates with differences in sensitivity to radiationinduced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res., 55: 12-15, 1995.
57. Honma, M., Hayashi, M., and Sofuni, T. Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutated human lymphoblastoid cells. Mutat. Res., 374: 89-98, 1997.
58. Liu, P. K., Kraus, E., Wu, T. A., Strong, L. C., and Tainsky, M. A. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene, 12: 2267-2278, 1996.
59. Strauss, B. S. Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis (Lond.), 18: 1445-1452, 1997.
60. Fishel, R. Genomic instability, mutators, and the development of cancer: is there a role for p53? J. Natl. Cancer Inst., 88: 1608-1609, 1996.
61. Kahlenberg, M. S., Stoler, D. L., Basik, M., Petrelli, N. J., Rodriguez-Bigas, M., and Anderson, G. R. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers. J. Natl. Cancer Inst., 88: 1665-1670, 1996.
62. Renault, B., Calistri, D., Buonsanti, G., Nanni, O., Amadori. D., and Ranzani. G. N, Microsatellite instability and mutations of p53 and TGF-β RII genes in gastric cancer. Hum. Genet., 98: 601-607, 1996.
63. Sands, A. T., Suraokar, M. B., Sanchez, A., Marth, J. E., Donehower, L. A., and Bradley. A. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc. Natl. Acad. Sci. USA, 92: 8517-8521, 1995.
64. Vijg. J., Mullaart, E., Van der Schans, G. P., Lohman, P. H., and Knook, D. L. Kinetics of ultraviolet induced DNA excision repair in rat and human fibroblasts. Mutat. Res., 132: 129-138, 1984.
65. van Loon, A. A., Timmeiman, A. J., Van der Schans, G. P., Lohman, P. H., and Baan, R. A. Different repair kinetics of radiation-induced DNA lesions in human and murine white blood cells. Carcinogenesis (Lond.), 13: 457-462. 1992.
66. Vrieling, H., Venema, J., van Rooyen, M. L., van Hoffen, A., Menichini, P., Zdzienicka, M. Z., Simons, J. W., Mullenders, L. H., and Van Zeeland, A. A. Strand specificity for UV-induced DNA repair and mutations in the Chinese hamster HPRT gene. Nucleic Acids Res., 19: 2411-2415, 1991.
67. Lane, D. P., and Benchimol, S. p53: oncogene or anti-oncogene. Genes Dev., 4: 1-8, 1990.
68. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-46, 1993.
69. Hsiao, M., Low, J., Dom, E., Ku, D., Pattengale, P., Yeargin, J., and Haas, M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol., 145: 702-714, 1994.
70. Hollstein, M., Shomer, B., Greenblatt, M., Soussi, T., Hovig, E., Montesano, R., and Harris, C. C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res., 24: 141-146, 1996.
71. Hainaut, P., Hemandez, T., Robinson, A., Rodriguez-Tome, P., Flores, T., Hollstein, M., Harris, C. C., and Montesano, R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res., 26: 205-213, 1998.
72. Soussi, T., Caron de Fromentel, C., and May, P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5: 945-952, 1990.
73. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
74. Greenblatt, M. S., Grollman, A. P., and Harris, C. C. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res., 56: 2130-2136, 1996.
75. Park, J. W., Cundy, K. C., and Ames, B. N. Detection of DNA adducts by high-performance liquid chromatography with electrochemical detection. Carcino-genesis (Lond.), 10: 827-832, 1989.
76. Gottlieb, T. M., and Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287: 77-102, 1996.
77. Harris, C. C. p53: at the crossroads of molecular Carcinogenesis and cancer risk assessment. Science (Washington DC), 262: 1980-1981, 1993.
78. Soussi, T., Legros, Y., Lubin, R., Ory, K., and Schlichtholz, B. Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer, 57: 1-9, 1994.
79. Kunkel, T. A. Misalignment-mediated DNA synthesis errors. Biochemistry, 29: 8003-8011, 1990.
80. Jego, N., Thomas, G., and Hamelin, R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene, 8: 209-213, 1993.
81. Krawczak, M., and Cooper, D. N. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum. Genet., 86: 425-441, 1991.
82. Liu, X., Miller, C. W., Koeffler, P. H., and Berk, A. J. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol., 13: 3291-3300, 1993.
83. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
84. Thut, C. J., Chen, J-L., Klemm, R., and Tjian, R. p53 transcriptional activation mediated by coactivators TAFii40 and TAFii;60. Science (Washington DC), 267: 100-104, 1995.
85. Lu, H., and Levine, A. J. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA, 92: 5154-5158, 1995.
86. Raycroft, L., Wu, H., and Lozano, G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (Washington DC), 249: 1049-1051, 1990.
87. Fields, S., and Jang, S. K. Presence of a potent transcription activating sequence in the p53 protein. Science (Washington DC), 249: 1046-1048, 1990.
88. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shenk, T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 89: 12028-12032, 1992.
89. Truant, R., Xiao, H., Ingles, C. J., and Greenblatt, J. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J. Biol. Chem., 268: 2284-2287, 1993.
90. Martin, D. W., Munoz, R. M., Subler, M. A., and Deb, S. p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem., 268: 13062-13067, 1993.
91. Mack, D. H., Vartikar, J., Pipas, J. M., and Laimins, L. A. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature (Lond.), 363: 281-283, 1993.
92. Lin, J., Chen, J., Elenbaas, B., and Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev., 8: 1235-1246, 1994.
93. Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., and Gronenborn, A. M. High-resolution solution structure of the oligomerization domain of p53 by multi-dimensional NMR. Science (Washington DC), 265: 386-391, 1994.
94. Jeffrey, P. D., Gorina, S., and Pavletich, N. P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (Washington DC), 267: 1498-1502, 1995.
95. Hupp, T. R., and Lane, D. P. Allosteric activation of latent p53 tetramers. Curr. Biol., 4: 865-875, 1995.
96. Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., and Arrowsmith, C. H. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol., 1: 877-890, 1994.
97. Jayaraman, L., and Prives, C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell, 81: 1021-1029, 1995.
98. Bakalkin, G., Yakovleva, T., Selivanova, G., Magnusson, K. P., Szekely, L., Kiseleva, E., Klein, G., Terenius, L., and Wiman, K. G. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA, 91: 413-417, 1994.
99. Horikoshi, N., Usheva, A., Chen, J., Levine, A. J., Weinmann, R., and Shenk, T. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol., 15: 227-234, 1995.
100. Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H. J., and Harris, C. C. The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev., 10: 1219-1232, 1996.
101. Milner, J., Medcalf, E. A., and Cook, A. C. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol., 11: 12-19, 1991.
102. Brain, R., and Jenkins, J. R. Human p53 directs DNA strand reassociation and is photolabelled by 8-azido ATP. Oncogene, 9: 1775-1780, 1994.
103. 1 cyclin-dependent kinases. Nature (Lond.), 376: 88-91, 1995.
104. Wu, L., Bayle, J. H., Elenbaas, B., Pavletich, N. P., and Levine, A. J. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol., 15: 497-504, 1995.
105. Bakalkin, G., Selivanova, G., Yakovleva, T., Kiseleva, E., Kashuba, E., Magnusson, K. P., Szekely, L., Klein, G., Terenius, L., and Wiman, K. G. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res., 23: 362-369, 1995.
106. 2 terminus of p53 facilitates transactivation. Cancer Res., 55: 2410-2417, 1995.
107. Hainaut, P., and Milner, J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res., 53: 4469-4473, 1993.
108. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res., 21: 3167-3174, 1993.
109. Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P., and Mann, K. Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol., 15: 3892-3903, 1995.
110. Gu, W., and Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90: 595-606, 1997.
111. Shaw, P., Freeman, J., Bovey, R., and Iggo, R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy terminus. Oncogene, 12: 921-930, 1996.
112. Okorokov, A. L., Ponchel, F., and Milner, J. Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. EMBO J., 16: 6008-6017, 1997.
113. Cho, Y., Gorina, S., Jeffrey, P., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: a framework for understanding how mutations inactivate p53. Science (Washington DC), 265: 346-355, 1994.
114. Borresen, A. L., Andersen, T. I., Eyfjord, J. E., Cornelis, R. S., Thorlacius, S., Borg, A., Johansson, U., Theillet, C., Schemeck, S., and Hartman, S. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer, 14: 71-75, 1995.
115. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
116. Taylor, E. M., Broughton, B. C., Botta, E., Stefanini, M., Sarasin, A., Jaspers, N. G., Fawcett, H., Harcourt, S. A., Arlett, C. F., and Lehmann, A. R. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc. Natl. Acad. Sci. USA, 94: 8658-8663, 1997.
117. Ehrlich, M., Zhang, X. Y., and Inamdar, N. M. Spontaneous deamination of cytosine and 5-methylcytosine residues in DNA and replacement of 5-methylcytosine residues with cytostne residues. Mutat. Res., 238: 277-286, 1990.
118. Forrester, K., Lupold, S. E., On, V. L., Chay, C. H., Band, V., Wang, X. W., and Harris, C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10: 2103-2111, 1995.
119. Denissenko, M. F., Pao, A., Tang, M., and Pfeifer, G. P. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in P53. Science (Washington DC), 274: 430-432, 1996.
120. Denissenko, M. F., Chen, J. X., Tang, M. S., and Pfeifer, G. P. Cytosine methylation determines hotspots of DNA damage in the human P53 gene. Proc. Natl. Acad. Sci. USA, 94: 3893-3898, 1997.
121. Chen, J. X., Zheng, Y., West, M., and Tang, M. S. Carcinogens preferentially bind at methylated CpG in the p53 mutational hotspots. Cancer Res., 58: 2070-2075, 1998.
122. Tornaletti, S., and Pfeifer, G. P. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science (Washington DC), 263: 1436-1438, 1994.
123. Hanawalt, P. C. Preferential DNA repair in expressed genes. Environ. Health Perspect., 76: 9-14, 1987.
124. Ford, J. M., Lommel, L., and Hanawalt, P. C. Preferential repair of ultraviolet light-induced DNA damage in the transcribed strand of the human p53 gene. Mol. Carcinog., 10: 105-109, 1994.
125. Evans, M. K., Taffe, B. G., Harris, C. C., and Bohr, V. A. DNA strand bias in the repair of the p53 gene in normal human and xeroderma pigmentosum group C fibroblasts. Cancer Res., 53: 5377-5381, 1993.
126. Hanawalt, P. C. Preferential repair of damage in actively transcribed DNA sequences in vivo. Genome, 31: 605-611, 1989.
127. Takeshima, Y., Seyama, T., Bennett, W. P., Akiyama, M., Tokuoka, S., Inai, K., Mabuchi, K., Land, C. E., and Harris, C. C. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet, 342: 1520-1521, 1993.
128. Bohr, V. A. Gene-specific DNA repair. Carcinogenesis (Lond.), 12: 1983-1992, 1991.
129. Ruggeri, B., DiRado, M., Zhang, S. Y., Bauer, B., Goodrow, T., and Klein-Szanto, A. J. Benzo(a)pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in thep53 gene. Proc. Natl. Acad. Sci. USA, 90: 1013-1017, 1993.
130. Bohr, V. A., Phillips, D. H., and Hanawalt, P. C. Heterogeneous DNA damage and repair in the mammalian genome. Cancer Res., 47: 6426-6436, 1987.
131. Holliday, R., and Grigg, G. W. DNA methylation and mutation. Mutat. Res., 285: 61-67, 1993.
132. Rideout, W. M., III, Coetzee, G. A., Olumi, A. F., and Jones, P. A. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science (Washington DC), 249: 1288-1290, 1990.
133. Mellon, I., Rajpal, D. K., Koi, M., Boland, C. R., and Champe, G. N. sequence-coupled repair deficiency and mutations in human mismatch repair genes. Science (Washington DC), 272: 557-560, 1996.
134. 1 checkpoint in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
135. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
136. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
137. Quesnel, B., Fenaux, P., Philippe, N., Fournier, J., Bonneterre, J., Preudhomme, C., and Peyrat, J. P. Analysis of p16 gene deletion and point mutation in breast carcinoma. Br. J. Cancer, 72: 351-353, 1995.
138. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res., 55: 1448-1451, 1995.
139. INK4A) somatic and germline mutations. Hum. Mutat., 7: 294-303, 1996.
140. Foulkes, W. D., Flanders, T. Y., Pollock, P. M., and Hayward, N. K. The CDKN2A (p16) gene and human cancer. Mol. Med., 3: 5-20, 1997.
141. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
142. Issa, J. P., and Baylin, S. B. Epigenetics and human disease. Nat. Med., 2: 281-282, 1996.
143. INK4a allele. J. Natl. Cancer Inst, 88: 1489-1491, 1996.
144. INK4 function. Nat. Genet., 10: 114-116, 1995.
145. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Hogden, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barren, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A., and Skolnick, M. H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Washington DC), 266: 66-71, 1994.
146. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., and Micklem, G. Identification of the breast cancer susceptibility gene BRCA2. Nature (Lond.), 378: 789-792, 1995.
147. Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., Belanger, C., Bell, R., Berry, S., Bogden, R., Chen, Q., Davis, T., Dumont, M., Frye, C., Hattier, T., Jammulapati, S., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J. F., and Goldgar, D. E. The complete BRCA2 gene and mutations in chromosome 13q-Iinked kindreds. Nat. Genet., 12: 333-337, 1996.
148. Cannon-Albright, L. A., Kamb, A., and Skolnick, M. A review of inherited predisposition to melanoma. Semin. Oncol., 23: 667-672, 1996.
149. Kamb, A., and Skolnick, M. H. Identification of the BRCA1 breast cancer gene and its clinical implications. Important Adv. Oncol., 23-35, 1996.
150. Stratton, M. R., and Wooster, R. Hereditary predisposition to breast cancer. Curr. Opin. Genet. Dev., 6: 93-97, 1996.
151. Gayther, S. A., and Ponder, B. A. Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Mol. Med. Today, 3: 168-174, 1997.
152. Easton, D. F., Ford, D., and Bishop, D. T. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet., 56: 265-271, 1995.
153. Gayther, S. A., Warren, W., Mazoyer, S., Russell, P. A., Harrington, P. A., Chiano, M., Seal, S., Hamoudi, R., van Rensburg, E. J., and Dunning, A. M. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat. Genet., 11: 428-433, 1995.
154. Gayther, S. A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B. A., Stratton, M. R., and Easton, D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat. Genet., 15: 103-105, 1997.
155. Schutte, M., da Costa, L. T., Hahn, S. A., Moskaluk, C., Hoque, A. T., Rozenblum, E., Weinstein, C. L., Bittner, M., Meltzer, P. S., and Trent, J. M. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc. Natl. Acad. Sci. USA, 92: 5950-5954, 1995.
156. Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., and Kern, S. E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res., 56: 5360-5364, 1996.
157. Friedman, L. S., Gayther, S. A., Kurosaki, T., Gordon, D., Noble, B., Casey, G., Ponder, B. A., and Anton-Culver, H. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am. J. Hum. Genet., 60: 313-319, 1997.
158. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weaver-Feldhaus, J., Ding, W., Gholami, Z., Soderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., lnglehart, J. D., Marks, J., Ballinger, D. G., Barren, J. C., Skolnick, M. H., Kamb, A., and Wiseman, R. BRCA1 mutations in primary breast and ovarian carcinomas. Science (Washington DC), 266: 120-122, 1994.
159. Merajver, S. D., Pham, T. M., Caduff, R. F., Chen, M., Poy. E. L., Cooney, K. A., Weber, B. L., Collins, F. S., Johnston, C., and Frank, T. S. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat. Genet., 9: 439-443, 1995.
160. Miki, Y., Katagiri, T., Kasumi, F., Yoshimoto, T., and Nakamura, Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat. Genet., 13: 245-247, 1996.
161. Lancaster, J. M., Wooster, R., Mangion, J., Phelan, C. M., Cochran, C., Gumbs, C., Seal, S., Barfoot, R., Collins, N., Bignell, G., Patel, S., Hamoudi, R., Larsson, C., Wiseman, R. W., Berchuck, A., Iglehart, J. D., Marks, J. R., Ashworth, A., Stratton, M. R., and Futreal, P. A. BRCA2 mutations in primary breast and ovarian cancers. Nat. Genet., 13: 238-240, 1996.
162. Foster, K, A., Harrington, P., Kerr, J., Russell, P., DiCioccio, R. A., Scott, I. V., Jacobs, I., Chenevix-Trench, G., Ponder, B. A., and Gayther, S. A. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res., 56: 3622-3625, 1996.
163. Shattuck-Eidens, D., McClure, M., Simard, J., Labrie, F., Narod, S., Couch, F., Hoskins, K., Weber, B., Castilla, L., and Erdos, M. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. J. Am. Med. Assoc., 273: 535-541, 1995.
164. FitzGerald, M. G., MacDonald, D. J., Krainer, M., Hoover, I., O'Neil, E., Unsal, H., Silva-Arrieto, S., Finkelstein, D. M., Beer-Romero, P., Englert, C., Sgroi, D. C., Smith, B. L., Younger, J. W., Garber, J. E., Duda, R. B., Mayzel, K. A., Isselbacher, K. J., Friend, S. H., and Haber, D. A. Germline BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N. Engl. J. Med., 334: 143-149, 1996.
165. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., and Tucker, M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336: 1401-1408, 1997.
166. Neuhausen, S., Gilewski, T., Norton, L., Tran, T., McGuire, P., Swensen, J., Hampel. H., Borgen, P., Brown, K., Skolnick, M., Shattuck-Eidens, D., Jhanwar, S., Goldgar, D., and Offit, K. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat. Genet., 13: 126-128, 1996.
167. Chapman, M. S., and Verma, I. M. Transcriptional activation by BRCA. Nature (Lond.), 382: 678-679, 1996.
168. Milner, J., Ponder, B., Hughes-Davies, L., Seltmann, M., and Kouzarides, T. Transcriptional activation functions in BRCA2. Nature (Lond.), 386: 772-773, 1997.
169. Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo. M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., Firpo, E., Hui, C. C., Roberts, J., Rossant, J., and Mak, T. W. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell, 85: 1009-1023, 1996.
170. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature (Lond.), 386: 804-810, 1997.
171. Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., and Mak, T. W. Partial rescue of Brcal (5-6) early embryonic lethality by p53 or p21 null mutation. Nat. Genet., 16: 298-302, 1997.
172. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D. M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 88: 265-275, 1997.
173. Patel, K. J., Yu, V. P. C. C., Lee, H., Corcoran, A., Thistlethwaite, F. C., Evans, M. J., Colledge, W. H., Friedman, L. S., Ponder, B. A., and Venkitaraman, A. R. Involvement of Brca2 in DNA repair. Mol. Cell, 1: 347-357, 1998.
174. Scharer, E., and lggo, R. Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res., 20: 1539-1545, 1992.
175. Ishioka, C., Englert, C., Winge, P., Yan, Y. X., Engelstein, M., and Friend, S. H. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene, 10: 1485-1492, 1995.
176. Moshinsky, D. J., and Wogan, G. N. UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA, 94: 2266-2271, 1997.
177. Aguilar, F., Harris, C. C., Sun, T., Hollstein, M., and Cerutti, P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science (Washington DC), 264: 1317-1319, 1994.
178. 1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA, 90: 8586-8590, 1993.
179. Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., and Harris, C. C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (Lond.), 350: 427-428, 1991.
180. Bressac, B., Kew, M., Wands, J., and Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (Lond.), 350: 429-431, 1991.
181. Scorsone, K. A., Zhou, Y. Z., Butel, J. S., and Slagle, B. L. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res., 52: 1635-1638, 1992.
182. Li, D., Cao, Y., He, L., Wang, N. J., and Gu, J. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis (Lond.), 14: 169-173, 1993.
183. Montesano, R., Hainaut, P., and Wild, C. P. Hepatocellular carcinoma: from gene to public health. J. Natl. Cancer Inst., 89: 1844-1851, 1997.
184. 1 induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis (Lond.), 18: 1291-1297, 1997.
185. Puisieux, A., Ji, J., Guillot, C., Legros, Y., Soussi, T., Isselbacher, K., and Ozturk, M. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc. Natl. Acad. Sci. USA, 92: 1342-1346, 1995.
186. Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., and Ponten, J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA, 88: 10124-10128, 1991.
187. Hsia, H. C., Lebkowski, J. S., Leong, P. M., Calos, M. P., and Miller, J. H. Comparison of ultraviolet irradiation-induced mutagenesis of the lacI gene in Escherichia coli and in human 293 cells. J. Mol. Biol, 205: 103-113, 1989.
188. Bredberg, A., Kraemer, K. H., and Seidman, M. M. Restricted ultraviolet mutational spectrum in a shuttle vector propagated in xeroderma pigmentosum cells. Proc. Natl. Acad. Sci. USA, 83: 8273-8277, 1986.
189. Brash, D. E. UV mutagenic photoproducts in Escherichia coli and human cells: a molecular genetics perspective on human skin cancer. Photochem. Photobiol., 48: 59-66, 1988.
190. Kress, S., Sutler, C., Strickland, P. T., Mukhtar, H., Schweizer, J., and Schwarz, M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res., 52: 6400-6403, 1992.
191. Tornaletti, S., Rozek, D., and Pfeifer, G. P. The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene, 8: 2051-2057, 1993.
192. Nakazawa, H., English, D., Randell, P. L., Nakazawa, K., Martel, N., Armstrong, B. K., and Yamasaki, H. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc. Natl. Acad. Sci. USA, 91: 360-364, 1994.
193. Ziegler, A., Jonason, A. S., Leffell, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., and Brash, D. E. Sunburn and p53 in the onset of skin cancer. Nature (Lond.), 372: 773-776, 1994.
194. Hernandez, T. M., and Hainaut, P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ. Health Perspect., 106: 385-391, 1998.
195. Klein-Szanto, A. J., lizasa, T., Momiki, S., Garcia-Palazzo, I., Caamano, J., Metcalf, R., Welsh, J., and Harris, C. C. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc. Natl. Acad. Sci. USA, 89: 6693-6697, 1992.
196. Hill, A. B. The environment and disease: association or causation. Proc. R. Soc. Med., 58: 295-300, 1965.
197. Sasa, M., Kondo, K., Komaki, K., Uyama, T., Morimoto, T., and Monden, Y. Frequency of spontaneous p53 mutations (CpG site) in breast cancer in Japan. Breast Cancer Res. Treat., 27: 247-252, 1993.
198. Tsuda, H., Iwaya, K., Fukutomi, T., and Hirohashi, S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn. J. Cancer Res., 84: 394-401, 1993.
199. Blaszyk, H., Vaughn, C. B., Hartmann, A., McGovern, R. M., Schroeder, J. I., Cunningham, J., Schaid, D., Sommer, S. S., and Kovach, J. S. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet, 343: 1195-1197, 1994.
200. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3547-3551, 1994.
201. Weinberg, R. A. Tumor suppressor genes. Science (Washington DC), 254: 1138-1146, 1991.
202. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F., Li, H., Wei, M. H., Chen, F., Glenn, G., Choyke, P., Walther, M. M., Weng, Y., Duan, D-S., Dean, M., Glavac, D., Richards, F. M., Crossey, P. A., Ferguson-Smith, M. A., Paslier, D. L., Chumakov, I., Cohen, D., Chinault, A. C., Maher, E. R., Linehan, W. M., Zbar, B., and Lerman, M. I. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (Washington DC), 260: 1317-1320, 1993.
203. Trofatter, J. A., MacCollin, M. M., Rutter, J. L., Murrell, J. R., Duyao, M. P., Parry, D. M., Eldridge, R., Kley, N., Menon, A. G., Pulaski, K., Haase, V. H., Ambrose, C. M., Munroe, D., Bove, C., Haines, J. L., Martuza, R. L., MacDonald, M. E., Seizinger, B. R., Short, M. P., Buckler, A. J., and Gusell, J. F. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell, 72: 791-800, 1993.
204. Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B., Pulst, S. M., Lenoir, G., Bijisma, E., Fashold, R., Dumanski, J., de Jong, P., Parry, D., Eldridge, R., Aurias, A., Delattre, O., and Thomas, G. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature (Lond.), 363: 515-521, 1993.
205. Schimke, R. N. Genetics and Cancer in Man, pp. 18-26. New York: Churchill Livingstone, Inc., 1978.
206. Soini, Y., Chia, S. C., Bennett, W. P., Groopman, J. D., Wang, J. S., DeBenedetti, V. M., Cawley, H., Welsh, J. A., Hansen, C., Bergasa, N. V., Jones, E. A., DiBisceglie, A. M., Trivers, G. E., Sandoval, C. A., Calderon, I. E., Munoz Espinosa, L. E., and Harris, C. C. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis (Lond.), 17: 1007-1012, 1996.
207. Wogan, G. N. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res., 52 (Suppl.): 2114s-2118s, 1992.
208. Ross, R. K., Yuan, J. M., Yu, M. C., Wogan, G. N., Qian, G. S., Tu, J. T., Groopman, J. D., Gao, Y. T., and Henderson, B. E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339: 943-946, 1992.
209. IARC. Mycotoxins: aflatoxins; studies of cancer in experimental animals. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, pp. 263-395. Lyon, France: IARC, 1993.
210. Autrup, H., Harris, C. C., Wu, S. M., Bao, L. Y., Pei, X. F., Lu, S., Sun, T. T., and Hsia, C. C. Activation of chemical carcinogens by cultured human fetal liver, esophagus and stomach. Chem.-Biol. Interact., 50: 15-25, 1984.
211. Pfeifer, A. M. A., Cole, K. E., Smoot, D. T., Weston, A., Groopman, J. D., Shields, P. G., Vignaud, J-M., Juillerat, M., Lipsky, M. M., Trump, B. F., Lechner, J. F., and Harris, C. C. SV40 T-antigen immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. USA, 90: 5123-5127, 1993.
212. Puisieux, A., Lim, S., Groopman, J., and Ozturk, M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res., 5: 6185-6189, 1991.
213. Wang, X. W., Gibson, M. K., Vermeulen, W., Yeh, H., Forrester, K., Sturzbecher, H. W., Hoeijmakers, J. H. J., and Harris, C. C. Abrogation of p53-induced apoptosis by the hepatitis B viras X gene. Cancer Res., 55: 6012-6016, 1995.
214. Ponchel, F., Puisieux, A., Tabone, E., Michot, J. P., Froschl, G., Morel, A. P., Frebourg, T., Fontaniere, B., Oberhammer, F., and Ozturk, M. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor β1-mediated apoptosis. Cancer Res., 54: 2064-2068, 1994.
215. Vahakangas, K. H., Samet, J. M., Metcalf, R. A., Welsh, J. A., Bennett, W. P., Lane, D. P., and Harris, C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet, 339: 576-580, 1992.
216. Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C. T., Pastorino, U., Della Porta, G., and Pierotti, M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res., 52: 6079-6082, 1992.
217. Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinha, G., Bleehen, N. M., and Rabbitts, P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene, 7: 1989-1997, 1992.
218. Chung, G. T., Sundaresan, V., Hasleton, P., Rudd, R., Taylor, R., and Rabbitts, P. H. Sequential molecular genetic changes in lung cancer development. Oncogene, 11: 2591-2598, 1995.
219. Chung, G. T., Sundaresan, V., Hasleton, P., Rudd, R., Taylor, R., and Rabbitts, P. H. Clonal evolution of lung tumors. Cancer Res., 56: 1609-1614, 1996.
220. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., Ro, J. Y., Broxson, A., Yu, R., Morice, R. C., Kemp, B. L., Khuri, F. R., Walsh, G. L., Hittelman, W. N., and Hong, W. K. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst., 89: 857-862, 1997.
221. Awaya, Y., Hiyama, K., and Yamakido, M. Analysis of oncogenes and suppressor genes in lung cancer and bronchial lesions from high risk group. Nippon Kyobu Shikkan Gakkai Zasshi, 30 (Suppl.): 39-41, 1992.
222. Wistuba, I. I., Lam, S., Behrens, C., Virmani, A. K., Fong, K. M., LeRiche, J., Samet, J. M., Srivastava, S., Minna, J. D., and Gazdar, A. F. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst., 59: 1366-1373, 1997.
223. IARC. Benzo(a)pyrene. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, pp. 211-224. Lyon, France: IARC, 1983.
224. Dipple, A. Polynuclear aromatic carcinogens. In: C. E. Searle (ed.), Chemical Carcinogens, pp. 245-314, Washington, DC: American Chemical Society, 1976.
225. IARC. Tobacco smoking. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 38. Lyon, France: IARC, 1986.
226. Harris, C. C., Genta, V. M., Frank, A. L., Kaufman, D. G., Barrett, L. A., McDowell, E. M., and Trump, B. F. Carcinogenic polynuclear hydrocarbons bind to macromolecules in cultured human bronchi. Nature (Lond.), 252: 68-69, 1974.
227. Jeffrey, A. M., Weinstein, I. B., Jennette, K. W., Grzeskowiak, K., Nakanishi, K., Harvey, R. G., Autrup, H., and Harris, C. C. Structures of benzo(a)pyrene-nucleic acid adducts formed in human and bovine bronchial explants. Nature (Lond.), 269: 348-350, 1977.
228. Cherpillod, P., and Amstad, P. A. Benzo(a)pyrene-induced mutagenesis of p53 hot-spot codons 248 and 249 in human hepatocytes. Mol. Carcinog., 13: 15-20, 1995.
229. Iizasa, T., Momiki, S., Bauer, B., Caamano, J., Metcalf, R., Lechner, J., Harris, C. C., and Klein-Szanto, A. J. Invasive tumors derived from xenotransplanted, immortalized human cells after in vivo exposure to chemical carcinogens. Carcinogenesis (Lond.), 14: 1789-1794, 1993.
230. Daya-Grosjean, L., Dumaz, N., and Sarasin, A. The specificity of p53 mutation spectra in sunlight-induced human cancers. J. Photochem. Photobiol. B Biol., 28: 115-124, 1995.
231. Nakazawa, H., English, D., Randell, P. L., Nakazawa, K., Martel, N., Armstrong, B. K., and Yamasaki, H. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc. Natl. Acad. Sci. USA, 91: 360-364, 1994.
232. IARC. Studies of cancer in animals. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, pp. 139-162. Lyon, France: IARC, 1992.
233. Dumaz, N., Drougard, C., Sarasin, A., and Daya-Grosjean, L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc. Natl. Acad. Sci. USA, 90: 10529-10533, 1993.